Compare NSPR & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | NEPH |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 35.3M |
| IPO Year | 2009 | 2004 |
| Metric | NSPR | NEPH |
|---|---|---|
| Price | $0.73 | $3.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.33 | ★ $6.08 |
| AVG Volume (30 Days) | ★ 336.1K | 58.1K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.17 |
| Revenue | $2,310,000.00 | ★ $18,789,000.00 |
| Revenue This Year | $9.14 | $17.81 |
| Revenue Next Year | $105.44 | $15.90 |
| P/E Ratio | ★ N/A | $18.15 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.43 | $2.66 |
| 52 Week High | $2.22 | $6.42 |
| Indicator | NSPR | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 49.48 |
| Support Level | $0.66 | $3.19 |
| Resistance Level | $0.77 | $3.78 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 74.86 | 62.38 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.